Canagliflozin for weight loss in non-diabetic individuals

Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is primarily used as an anti-diabetic medication, but recent evidence suggests its potential role in promoting weight loss individuals without diabetes. A comprehensive literature review was conducted, analysing relevant studies published between 2013-2021, focusing on the efficacy and safety of canagliflozin for non-diabetic populations. Four were identified, which consistently demonstrated that treatment resulted significant compared to placebo or other comparators. The effect appears be mediated by increased urinary glucose excretion, caloric loss, reduction body fat mass. Canagliflozin also showed improvements cardiometabolic risk factors, such blood pressure lipid profiles. This review, therefore, provides substantial supporting use effective individuals, suggesting it could valuable therapeutic option addressing rising prevalence obesity associated comorbidities. However, further well-designed clinical trials are needed elucidate optimal dosing, long-term safety, side effects this specific population.